AR045811A1 - 5- arilpirimidinas como agentes ainticancerigenos - Google Patents

5- arilpirimidinas como agentes ainticancerigenos

Info

Publication number
AR045811A1
AR045811A1 ARP040103441A ARP040103441A AR045811A1 AR 045811 A1 AR045811 A1 AR 045811A1 AR P040103441 A ARP040103441 A AR P040103441A AR P040103441 A ARP040103441 A AR P040103441A AR 045811 A1 AR045811 A1 AR 045811A1
Authority
AR
Argentina
Prior art keywords
alkyl
mammal
compounds
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP040103441A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR045811A1 publication Critical patent/AR045811A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP040103441A 2003-09-24 2004-09-23 5- arilpirimidinas como agentes ainticancerigenos AR045811A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50548703P 2003-09-24 2003-09-24

Publications (1)

Publication Number Publication Date
AR045811A1 true AR045811A1 (es) 2005-11-16

Family

ID=34393022

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103441A AR045811A1 (es) 2003-09-24 2004-09-23 5- arilpirimidinas como agentes ainticancerigenos

Country Status (24)

Country Link
US (1) US7524849B2 (enExample)
EP (1) EP1663241B1 (enExample)
JP (1) JP2007506746A (enExample)
KR (1) KR20060089215A (enExample)
CN (1) CN1871009A (enExample)
AR (1) AR045811A1 (enExample)
AT (1) ATE432077T1 (enExample)
AU (1) AU2004275733A1 (enExample)
BR (1) BRPI0414736A (enExample)
CA (1) CA2539235A1 (enExample)
CO (1) CO5690592A2 (enExample)
DE (1) DE602004021269D1 (enExample)
EC (1) ECSP066457A (enExample)
GT (1) GT200400188A (enExample)
IL (1) IL174305A0 (enExample)
MX (1) MXPA06003207A (enExample)
NO (1) NO20061319L (enExample)
PA (1) PA8613201A1 (enExample)
PE (1) PE20050470A1 (enExample)
RU (1) RU2006107578A (enExample)
SA (1) SA04250303A (enExample)
TW (1) TW200512198A (enExample)
WO (1) WO2005030216A1 (enExample)
ZA (1) ZA200602386B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
EP1891052A1 (en) * 2005-06-13 2008-02-27 Wyeth Tubulin inhibitor and process for its preparation
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
US20110201496A1 (en) * 2006-03-27 2011-08-18 Joachim Rheinheimer Substituted 5-Hetaryl-4-Aminopyrimidines
CL2007002231A1 (es) * 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
AR064852A1 (es) * 2007-01-11 2009-04-29 Basf Ag Pirimidinas sustituidas en posicion 2
WO2009007187A1 (de) * 2007-07-09 2009-01-15 Basf Se Substituierte 5-hetarylpyrimidine
PE20140502A1 (es) 2011-04-22 2014-05-02 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
WO2014047257A2 (en) 2012-09-19 2014-03-27 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
BR112017012795A2 (pt) 2014-12-16 2018-01-02 Signal Pharmaceuticals, Llc Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ,エルエルシー 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX2018001004A (es) 2015-07-24 2018-06-07 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este.
WO2019169111A1 (en) 2018-03-02 2019-09-06 The Trustees Of The University Of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
EP4052759A4 (en) * 2019-11-01 2023-12-20 Unimatec Co., Ltd. FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88096A (en) * 1869-03-23 t h a y e r
US116429A (en) * 1871-06-27 Improvement in dial-telegraph apparatus
US61889A (en) * 1867-02-05 Improvement in animal teaps
US69242A (en) * 1867-09-24 Calvin pepper
US147744A (en) * 1874-02-24 Improvement in locomotive-furnaces
GB9700664D0 (en) 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
US6117876A (en) 1997-04-14 2000-09-12 American Cyanamid Company Fungicidal trifluorophenyl-triazolopyrimidines
AU3536699A (en) 1998-04-27 1999-11-16 Ihara Chemical Industry Co. Ltd. 3-arylphenyl sulfide derivatives and insecticides and miticides
US5986135A (en) 1998-09-25 1999-11-16 American Cyanamid Company Fungicidal trifluoromethylalkylamino-triazolopyrimidines
US6156925A (en) 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
AU778913B2 (en) * 2000-06-13 2004-12-23 Basf Aktiengesellschaft Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
WO2002074753A2 (de) 2001-03-15 2002-09-26 Basf Aktiengesellschaft 5-phenylpyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekaempfung von schadpilzen
DE60204509T2 (de) 2001-04-20 2006-03-16 Ciba Speciality Chemicals Holding Inc. 4-Amino-2-(2-pyridinyl)pyrimidine als mikrobizide Wirksubstanzen
CN1312134C (zh) 2001-11-19 2007-04-25 巴斯福股份公司 5-苯基嘧啶化合物、包含它们的组合物、其制备方法及其用途
ATE428705T1 (de) 2002-02-21 2009-05-15 Basf Se 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
CN1642422A (zh) 2002-03-15 2005-07-20 西巴特殊化学品控股有限公司 4-氨基嘧啶及其在表面抗菌处理中的应用
PT2316831E (pt) 2002-11-21 2013-06-06 Novartis Ag 2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro

Also Published As

Publication number Publication date
EP1663241B1 (en) 2009-05-27
US20050075357A1 (en) 2005-04-07
PA8613201A1 (es) 2005-11-25
BRPI0414736A (pt) 2006-11-21
TW200512198A (en) 2005-04-01
ECSP066457A (es) 2006-09-18
RU2006107578A (ru) 2007-10-27
CN1871009A (zh) 2006-11-29
EP1663241A1 (en) 2006-06-07
SA04250303A (ar) 2005-12-03
JP2007506746A (ja) 2007-03-22
WO2005030216A1 (en) 2005-04-07
GT200400188A (es) 2005-05-02
PE20050470A1 (es) 2005-10-03
KR20060089215A (ko) 2006-08-08
ZA200602386B (en) 2009-03-25
CO5690592A2 (es) 2006-10-31
DE602004021269D1 (de) 2009-07-09
MXPA06003207A (es) 2006-06-23
US7524849B2 (en) 2009-04-28
NO20061319L (no) 2006-04-20
CA2539235A1 (en) 2005-04-07
IL174305A0 (en) 2008-02-09
AU2004275733A1 (en) 2005-04-07
ATE432077T1 (de) 2009-06-15

Similar Documents

Publication Publication Date Title
AR045811A1 (es) 5- arilpirimidinas como agentes ainticancerigenos
JP2008535902A5 (enExample)
MX2023006145A (es) Inhibidores de prmt5 novedosos.
IL261852A (en) Substituted imidazole based compounds for treatment of cancer
RU2015143542A (ru) Ингибиторы jak2 и alk2 и способы их использования
MY206521A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JP2008535903A5 (enExample)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2014503567A5 (enExample)
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2011150250A (ru) Антагонисты пути hedgehog и их терапевтическое применение
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
RU2013112871A (ru) Соединения для лечения рака
JP2013538213A5 (enExample)
CA2626032A1 (en) Camptothecin derivatives as chemoradiosensitizing agents
CN110769837A (zh) 与五氮杂大环状环配合物的联合癌症免疫疗法
RU2016138676A (ru) Ингибиторы усилителя zeste гомолога 2
CY1123161T1 (el) Παραγωγα δι(φαινυλοπροπανοειδους) γλυκερολης για τη θεραπεια του καρκινου
RU2013136861A (ru) Новое производное индола или индазола или его соль
IS5588A (is) Æxliseyðandi miðlar
JP2017503753A5 (enExample)
EA200701780A1 (ru) Противоопухолевое средство
TW200512211A (en) 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents
WO2016205460A4 (en) Polycyclic derivatives targeting ral gtpases and their therapeutical applications
RU2017133419A (ru) Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal